Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,775 public trials 502 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

NCT02783300

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +38 more
Locations
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Miami, Florida, United States
  • GSK Investigational Site New York, United States
  • GSK Investigational Site Nashville, Tennessee, United States
View all 15 locations
View Trial Details
Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

NCT05619744

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +18 more
Locations
  • Georgetown Uni Medical Center Washington D.C., District of Columbia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Henry Ford Hospital Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 17 locations
View Trial Details
Completed

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

NCT05340621

Conditions
Melanoma, NRAS Gene Mutation, Neoplasms, +11 more
Locations
  • CTCA Phoenix, part of City of Hope Phoenix, Arizona, United States
  • University of California, San Francisco San Francisco, California, United States
  • University of Florida Health Cancer Center Gainesville, Florida, United States
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
View Trial Details
Completed

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

NCT05697198

Conditions
Adnexal Diseases, Breast Cancer, Breast Diseases, +68 more
Locations
  • Clinical Site Fort Payne, Alabama, United States
  • Clinical Site Orange City, Florida, United States
  • Clinical Site Stuart, Florida, United States
  • Clinical Site Dublin, Georgia, United States
View Trial Details
Completed

MGD019 DART® Protein in Unresectable/Metastatic Cancer

NCT03761017

Conditions
Advanced Cancer, Colonic Diseases, Colorectal Cancer, +24 more
Locations
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 39 locations
View Trial Details

Related conditions